Panel Discussion

Tuesday, July 14, 2026

11:00 AM - 11:30 AM East Coast USA Time

Location: Kojo Kamau A

Speaker(s)

JA

Josh T. Albert, BSc

Principal Scientist
GlaxoSmithKline
Exton, Pennsylvania
Quentin Burke (he/him/his)

Principal Research Associate
Moderna Inc.
Norwood
HS

Harpinder Saini

Sr. Scientist
Genentech, Inc.
South San Francisco
Lin Yang, PhD (she/her/hers)

Director
AstraZeneca
Gaithersburg, Maryland

High baseline positivity in drug-naïve samples challenged ADC ADA assay development by inflating the assay cut point and reducing sensitivity. This presentation will show how root-cause investigations identified pre-existing anti-PEG IgM–mediated interference as the key driver and how a targeted mitigation strategy successfully restored assay performance and supported clinical readiness.